ReviewCancer medicine2026
Driver Gene Mutations Reprogram Lipid Metabolism in Non-Small Cell Lung Cancer.
Review in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Non-small cell lung cancer (NSCLC) is among the leading causes of cancer-related deaths worldwide. Previous treatment regimens often have limited efficacy due to drug resistance and recurrence. Metabolic reprogramming participates in the initiation and progression of NSCLC, with prominent changes in lipid metabolism. Mutations in specific driver genes directly remodel lipid metabolic reprogramming in NSCLC by rewiring lipid synthesis, uptake, and catabolism, which confers cancer cells with enhanced proliferative and metastatic capacity. On this basis, targeted lipid metabolism reprogramming has become a promising new direction for the treatment of NSCLC. In this review, we examined the alterations in lipid metabolism in NSCLC, explored the mechanisms by which driver gene mutations change lipid metabolism in NSCLC, and provided possible therapeutic strategies targeting key lipid metabolism pathways at the current stage, aiming to offer a theoretical basis and prospects for the development of novel therapies targeting specific gene mutation subtypes of NSCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.